Key facts
- It has raised $3.3M; the latest was Seed Round ($3.1M) in Feb 2025.
- Notable investors include Boldbrain, USI Startup Centre.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for InVirtuoLabs
- ·The full record, as it builds
Funding rounds
No funding rounds for InVirtuoLabs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InVirtuoLabs
Developer of novel drugs platform by using artificial intelligence and machine learning methods designed to accelerate the drug discovery process. The company's platform combines advanced machine learning techniques including multimodal learning, active learning, and generative chemistry with physics-based simulations, to explore vast chemical spaces with unprecedented efficiency, enabling users to reduce processing time and rapidly identify and optimize promising drug candidates.
- Sector
- Healthcare
- HQ
- Lugano, Switzerland
- Founded
- 2024
- Employees
- 9
- Website
- invirtuolabs.com/
- Ownership
- Privately Held (backing)
InVirtuoLabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InVirtuoLabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InVirtuoLabs in its N-PORT filings yet. We sweep new filings monthly.